EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Twareat Medical Care Company (9627) fair value: what the stock is really worth

We calculate from audited financials what Twareat Medical Care Company is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · SA

TM Thin data Sep 13, 2026

Twareat Medical Care Company

9627 · SR

Weakest SetupStrongly overvalued and low quality.

!Fair value 2.36 SAR · Strongly overvalued (−75%)
!Quality 41/100
!Expensive Growth (revenue 3y +7.0 %/yr)
!Loss-making · -5.6% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (3/11)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
Watch Twareat Medical Care Company for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

14.20 SAR 7.40 SAR Fair Value 2.36 SAR Dec 2025 Sep 2026

White line = price, green steps = our fair value per fiscal year. As of Sep 13, 2026.

How to read this chart

9‑month range 7.40 SAR – 14.20 SAR · fair‑value band 1.83 SAR – 2.83 SAR · the 9.30 SAR price screens above the 2.36 SAR fair value. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Twareat Medical Care Company provides medical care services in remote and industrial areas in the Kingdom of Saudi Arabia. It offers home care; medical evacuation and transportation; medical support; occupational, industrial, and remote area clinics services.

Show more

Twareat Medical Care Company provides medical care services in remote and industrial areas in the Kingdom of Saudi Arabia. It offers home care; medical evacuation and transportation; medical support; occupational, industrial, and remote area clinics services. The Group is engaged in general construction of residential buildings, renovation of residential and non-residential; buildings, stores of medical devices and products, hospitals, medical operations of hospitals, general medical; complexes, medical operations of medical complexes and one-day surgery centers, ambulance service centers, medical laboratories, home medical service centers, medical clinic mobile, telemedicine and telemedicine centers, medical operations of medical laboratories, radiology centers and supporting medical services, activities of drug stores, retail sale of medical devices, equipment and supplies, repair and maintenance of medical equipment and transformation of vehicles to medical equipment. Twareat Medical Care Company was founded in 2010 and is based in Al Khobar, the Kingdom of Saudi Arabia.

Stock analysis

Twareat Medical Care Company (9627) currently trades at 9.30 SAR, while our model-based Fair Value estimate is 2.36 SAR, implying the stock looks roughly 294.0% overvalued today.

Show more

Valuation

Bull case: the Dividend Discount group reads highest at a median of 2.54 SAR per share, and 0 of the 3 models we run sit above the 9.30 SAR price.

Bear case: the Asset-Based group reads lowest at 0.7800 SAR, and 3 of the 3 models stay below the price. Evidence for this calculation is low.

Scenario range: 1.83 SAR (bear) to 2.83 SAR (bull), the price of 9.30 SAR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Twareat Medical Care Company reported revenue of 183M SAR in FY2025 versus 150M SAR in FY2022, a compound +7.0%/yr. Reported net income was −10.3M SAR in FY2025.

Key figures

Market cap 372M SAR (≈ $99.0M) · P/S ratio 2.03 · EPS (TTM) −0.2600 SAR · Dividend yield 2.7% · Net margin −5.6% · Return on equity −18.1% · Return on assets (EBIT) 16.7% · Operating margin −15.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 35% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 0% fair-value upside, at −75%, 9627 screens richer than that median.

Fair Value models

Bear 1.83 SAR Fair Value 2.36 SAR Bull 2.83 SAR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Gordon GGM 1.94 SAR 2.54 SAR 3.09 SAR 67
DDM Multi-Stage 1.94 SAR 2.55 SAR 3.19 SAR 65
NCAV (Graham) 0.5800 SAR 0.7800 SAR 1.17 SAR 54
All 3 models by family
Dividend Discount
Gordon GGM 1.94 SAR 2.54 SAR 3.09 SAR 67
DDM Multi-Stage 1.94 SAR 2.55 SAR 3.19 SAR 65
Asset-Based
NCAV (Graham) 0.5800 SAR 0.7800 SAR 1.17 SAR 54

Open the full fair value analysis →

Notify me when 9627 reaches fair value

Put 9627 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 41/100

Of which business quality 42 · Market factors (momentum, volatility) 28

Profitability 35
Margins and returns on capital today
Quality Growth 16
Are margins and returns improving?
Cashflow 10
Earnings quality: real cash, not paper profit
Fin. Strength 60
Balance sheet, leverage, solvency risk
Investment 70
Disciplined investing over empire-building
Low Volatility 32
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 14
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 22/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−4.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
18.0% (2022) → −3.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

9627 screens 294% overvalued. Compare with HCA Healthcare, Inc →

Compare Twareat Medical Care Company with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 257 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside −75% · Bottom 25%
Profitability
Return on assets −4% · Bottom 25%
Net margin (TTM) −6% · Bottom 25%
Operating margin (TTM) −16% · Bottom 25%
Growth and dividend
Revenue growth −7% · Bottom 25%
Dividend yield (TTM) 2.7% · Above median
Balance sheet
Debt / equity 0.07× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 2.12× · Pricier than median
P/S (TTM) 0.54× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 30
FUTURE (revenue growth)0 · sector 27
PAST (return on equity)0 · sector 31
HEALTH (low debt)96 · sector 90
DIVIDEND (yield)54 · sector 43

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $426.94 $506.40 +19%
Fresenius SE FRE €45.04 €32.15 −29%
Dr. Sulaiman Al Habib Medical Services Group 4013 232.70 SAR 112.37 SAR −52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.67 SGD 1.51 SGD −43%
Tenet Healthcare Corporation THC $263.69 $294.55 +12%
DaVita Inc DVA $181.55 $180.71 +0%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,850 ₹2,955 −67%
Fresenius Medical Care AG FME €38.44 €71.28 +85%
Aier Eye Hospital Group 300015 ¥8.06 ¥10.86 +35%
Encompass Health Corporation EHC $121.71 $93.95 −23%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Twareat Medical Care Company · Fair Value
2.36 SAR −294%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Twareat Medical Care Company Fair Value". https://www.fairvalue-calculator.com/stock/9627

Frequently asked questions

Is Twareat Medical Care Company (9627) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 2.36 SAR versus a price of 9.30 SAR, about −75% upside (overvalued).
What is the fair value of 9627?
Our model-based fair value for Twareat Medical Care Company is 2.36 SAR (as of Sep 13, 2026), built from audited fundamentals. The current price: 9.30 SAR.
What is the quality score of 9627?
Twareat Medical Care Company has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Twareat Medical Care Company (9627)?
Our model-based price target is the fair value of 2.36 SAR (as of Sep 13, 2026) from 3 valuation models. Cautious scenario 1.83 SAR, optimistic scenario 2.83 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Twareat Medical Care Company stock forecast for 2026?
Our models put fair value at 2.36 SAR, about −75% upside versus a price of 9.30 SAR (overvalued). Cautious scenario 1.83 SAR, optimistic scenario 2.83 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Twareat Medical Care Company (9627)?
Twareat Medical Care Company reported trailing-twelve-month revenue of about 183M SAR (latest available figure, as of Sep 13, 2026).
Does Twareat Medical Care Company pay a dividend?
Twareat Medical Care Company currently shows a dividend yield of about 2.68% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Twareat Medical Care Company (9627)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Twareat Medical Care Company it is 2.36 SAR per share (as of Sep 13, 2026), against a price of 9.30 SAR. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Twareat Medical Care Company stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 9627 trades above its calculated fair value: price 9.30 SAR, fair value 2.36 SAR, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9627?
No. The price is what the market pays today (9.30 SAR); the fair value is what the company's own numbers justify (2.36 SAR). For Twareat Medical Care Company the two are 6.94 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Twareat Medical Care Company worth?
The market values Twareat Medical Care Company at about 372M SAR (market capitalisation, as of Sep 13, 2026). Per share that is 9.30 SAR; our models calculate a fair value of 2.36 SAR per share.
What do the bullish and bearish scenarios say about 9627?
Our models span a range for Twareat Medical Care Company: cautious scenario 1.83 SAR, base 2.36 SAR, optimistic 2.83 SAR per share (as of Sep 13, 2026, price 9.30 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Twareat Medical Care Company (9627)?
Balance-sheet figures for Twareat Medical Care Company (as of Sep 13, 2026): return on equity −18.1%, debt of 0.07 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 9627 from its 52-week high?
Twareat Medical Care Company trades at 9.30 SAR, about 35% below its 52-week high of 14.20 SAR and 26% above the low of 7.40 SAR (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 2.36 SAR is for.
Which stocks are comparable to Twareat Medical Care Company?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Twareat Medical Care Company stock attractive at the current price?
The data as of Sep 13, 2026: price 9.30 SAR, calculated fair value 2.36 SAR (−75%), Quality Score 41/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9627 calculated?
We run Twareat Medical Care Company through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2.36 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6 % above its aggregate fair value. Twareat Medical Care Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Twareat Medical Care Company (9627)?
The closing price on Sep 10, 2026 was 9.30 SAR. Our model-based fair value is 2.36 SAR, about −75% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Twareat Medical Care Company right now?
The price sits above even our optimistic bull case (2.83 SAR). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Twareat Medical Care Company

How large is the market capitalisation of Twareat Medical Care Company (9627)?
The market capitalisation of Twareat Medical Care Company is 372M SAR (≈ $99.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Twareat Medical Care Company (9627)?
The price-to-sales ratio of Twareat Medical Care Company is 2.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Twareat Medical Care Company (9627)?
Earnings per share at Twareat Medical Care Company are −0.2600 SAR. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Twareat Medical Care Company (9627)?
The dividend yield of Twareat Medical Care Company is 2.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Twareat Medical Care Company (9627)?
The net margin of Twareat Medical Care Company is −5.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Twareat Medical Care Company (9627)?
The return on equity (ROE) of Twareat Medical Care Company is −18.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Twareat Medical Care Company (9627)?
On an EBIT basis the return on assets of Twareat Medical Care Company is 16.7% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Twareat Medical Care Company (9627)?
The operating margin of Twareat Medical Care Company is −15.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Twareat Medical Care Company (9627)?
Revenue at Twareat Medical Care Company is growing −7.2% versus a year earlier (3y avg +7.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Twareat Medical Care Company (9627)?
Earnings per share at Twareat Medical Care Company are growing −65.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Twareat Medical Care Company (9627) generate?
The free cash flow of Twareat Medical Care Company is −6.7M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Twareat Medical Care Company (9627) carry?
The net debt of Twareat Medical Care Company is 26.9M SAR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Twareat Medical Care Company in the live analysis

One click puts Twareat Medical Care Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.